Black Diamond Therapeutics
BDTX
BDTX
86 hedge funds and large institutions have $64.1M invested in Black Diamond Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
48% less capital invested
Capital invested by funds: $124M → $64.1M (-$59.5M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $192K
Holders
86
Holding in Top 10
–
Calls
$3K
Puts
$192K
Top Buyers
| 1 | +$781K | |
| 2 | +$360K | |
| 3 | +$306K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$298K |
| 5 |
Two Sigma Investments
New York
|
+$295K |
Top Sellers
| 1 | -$1.45M | |
| 2 | -$937K | |
| 3 | -$777K | |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$471K |
| 5 |
Renaissance Technologies
New York
|
-$335K |